Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: A plausible explanation for altered metabolism of ivermectin in humans?

BMC Medical Genetics

Volumn 11, Issue 1, 2010, Pages

  Kudzi, William ^a,b   Dodoo, Alexander N O ^b   Mills, Jeremy J ^a  

^a UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^b UNIVERSITY OF GHANA   (Ghana)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; IVERMECTIN; MULTIDRUG RESISTANCE PROTEIN 1; ABCB1 PROTEIN, HUMAN; ANTIPARASITIC AGENT; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; DNA; GLYCOPROTEIN P;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GHANA; HAPLOTYPE; HUMAN; MALE; ONCHOCERCIASIS; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TREATMENT RESPONSE; BLOOD; GENETICS; GENOTYPE; ISOLATION AND PURIFICATION; METABOLISM; MULTIDRUG RESISTANCE;

ANTIPARASITIC AGENTS; CYTOCHROME P-450 CYP3A; DNA; DRUG RESISTANCE, MULTIPLE; GENE FREQUENCY; GENOTYPE; GHANA; HUMANS; IVERMECTIN; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 77955350444     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-11-111     Document Type: Article

References (47)

1. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I, Dey S. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998, 37(11):3594-3601. 10.1021/bi972709x, 9530286.
2. Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 2003, 43:285-307. 10.1146/annurev.pharmtox.43.100901.140233, 12359865.
3. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989, 86(2):695-698. 10.1073/pnas.86.2.695, 286540, 2563168.
4. MacFarland A, Abramovich DR, Ewen SW, Pearson CK. Stage-specific distribution of P-glycoprotein in first-trimester and full-term human placenta. Histochem J 1994, 26(5):417-423. 10.1007/BF00160054, 7913921.
5. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987, 84(21):7735-7738. 10.1073/pnas.84.21.7735, 299375, 2444983.
6. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 2003, 4(4):397-410. 10.1517/phgs.4.4.397.22747, 12831320.
7. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000, 97(7):3473-3478. 10.1073/pnas.050585397, 16264, 10716719.
8. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004, 75(1):13-33. 10.1016/j.clpt.2003.09.012, 14749689.
9. Horinouchi M, Sakaeda T, Nakamura T, Morita Y, Tamura T, Aoyama N, Kasuga M, Okumura K. Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm Res 2002, 19(10):1581-1585. 10.1023/A:1020433422259, 12425480.
10. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003, 13(8):481-494. 10.1097/00008571-200308000-00006, 12893986.
11. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996, 6(1):1-42. 10.1097/00008571-199602000-00002, 8845856.
12. Ayrton A, Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 2001, 31(8-9):469-497. 10.1080/00498250110060969, 11569523.
13. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994, 270(1):414-423.
14. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001, 27(4):383-391. 10.1038/86882, 11279519.
15. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997, 283(3):1552-1562.
16. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, Nuessler A, Neuhaus P, Eichelbaum M, Zanger U, et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 2002, 30(10):1108-1114. 10.1124/dmd.30.10.1108, 12228187.
17. Zeng Z, Andrew NW, Arison BH, Luffer-Atlas D, Wang RW. Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes. Xenobiotica 1998, 28(3):313-321. 10.1080/004982598239597, 9574819.
18. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002, 54(10):1271-1294. 10.1016/S0169-409X(02)00066-2, 12406645.
19. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998, 90(16):1225-1229. 10.1093/jnci/90.16.1225, 9719084.
20. Felix CA, Walker AH, Lange BJ, Williams TM, Winick NJ, Cheung NK, Lovett BD, Nowell PC, Blair IA, Rebbeck TR. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 1998, 95(22):13176-13181. 10.1073/pnas.95.22.13176, 23750, 9789061.
21. Eiselt R, Domanski TL, Zibat A, Mueller R, Presecan-Siedel E, Hustert E, Zanger UM, Brockmoller J, Klenk HP, Meyer UA, et al. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 2001, 11(5):447-458. 10.1097/00008571-200107000-00008, 11470997.
22. Ho H, Pinto A, Hall SD, Flockhart DA, Li L, Skaar TC, Cadman P, O'Connor DT, Wagner U, Fineberg NS, et al. Association between the CYP3A5 genotype and blood pressure. Hypertension 2005, 45(2):294-298. 10.1161/01.HYP.0000151361.31736.96, 15596575.
23. Control WECoO Onchocerciasis and its control. Technical Report Series No 852 1995, Control WECoO.
24. Benet LZ, Cummins CL, Wu CY. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. International journal of pharmaceutics 2004, 277(1-2):3-9. 10.1016/j.ijpharm.2002.12.002, 15158963.
25. Dadzie Y, Neira M, Hopkins D. Final report of the Conference on the eradicability of Onchocerciasis. Filaria J 2003, 2(1):2. 10.1186/1475-2883-2-2, 150378, 12605722.
26. Awadzi K, Boakye DA, Edwards G, Opoku NO, Attah SK, Osei-Atweneboana MY, Lazdins-Helds JK, Ardrey AE, Addy ET, Quartey BT, et al. An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol 2004, 98(3):231-249. 10.1179/000349804225003253, 15119969.
27. Awadzi K, Attah SK, Addy ET, Opoku NO, Quartey BT, Lazdins-Helds JK, Ahmed K, Boatin BA, Boakye DA, Edwards G. Thirty-month follow-up of sub-optimal responders to multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol 2004, 98(4):359-370. 10.1179/000349804225003442, 15228717.
28. Ardelli BF, Guerriero SB, Prichard RK. Genomic organization and effects of ivermectin selection on Onchocerca volvulus P-glycoprotein. Mol Biochem Parasitol 2005, 143(1):58-66. 10.1016/j.molbiopara.2005.05.006, 15993957.
29. Whatman FTA Protocol. , http://www.whatman.com
30. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001, 69(3):169-174. 10.1067/mcp.2001.114164, 11240981.
31. Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, Thornton N, Folayan GO, Githang'a J, Indalo A, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001, 11(3):217-221. 10.1097/00008571-200104000-00005, 11337937.
32. van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 2002, 48(10):1668-1671.
33. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2003, 13(2):89-95. 10.1097/00008571-200302000-00005, 12563178.
34. Anglicheau D, Verstuyft C, Laurent-Puig P, Becquemont L, Schlageter MH, Cassinat B, Beaune P, Legendre C, Thervet E. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003, 14(7):1889-1896. 10.1097/01.ASN.0000073901.94759.36, 12819250.
35. Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A, Ohdo S, Ohtani H, Sawada Y, Higuchi S, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002, 72(2):209-219. 10.1067/mcp.2002.126177, 12189368.
36. Allabi AC, Gala JL, Desager JP, Heusterspreute M, Horsmans Y. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol 2003, 56(6):653-657. 10.1046/j.1365-2125.2003.01937.x, 1884305, 14616425.
37. Tayeb MT, Clark C, Ameyaw MM, Haites NE, Evans DA, Tariq M, Mobarek A, Ofori-Adjei D, McLeod HL. CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations. Pharmacogenetics 2000, 10(8):753-756. 10.1097/00008571-200011000-00009, 11186137.
38. Zeigler-Johnson CM, Walker AH, Mancke B, Spangler E, Jalloh M, McBride S, Deitz A, Malkowicz SB, Ofori-Adjei D, Gueye SM, et al. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered 2002, 54(1):13-21. 10.1159/000066695, 12446983.
39. Garsa AA, McLeod HL, Marsh S. CYP3A4 and CYP3A5 genotyping by Pyrosequencing. BMC Med Genet 2005, 6:19. 10.1186/1471-2350-6-19, 1142317, 15882469.
40. Balram C, Zhou Q, Cheung YB, Lee EJ. CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations. Eur J Clin Pharmacol 2003, 59(2):123-126.
41. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001, 11(9):773-779. 10.1097/00008571-200112000-00005, 11740341.
42. Bosch TM, Doodeman VD, Smits PH, Meijerman I, Schellens JH, Beijnen JH. Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population. Mol Diagn Ther 2006, 10(3):175-185.
43. Boatin BA. The current state of the Onchocerciasis Control Programme in West Africa. Trop Doct 2003, 33(4):209-214.
44. Kerboeuf D, Blackhall W, Kaminsky R, von Samson-Himmelstjerna G. P-glycoprotein in helminths: function and perspectives for anthelmintic treatment and reversal of resistance. Int J Antimicrob Agents 2003, 22(3):332-346. 10.1016/S0924-8579(03)00221-8, 13678840.
45. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001, 40(3):159-168. 10.2165/00003088-200140030-00002, 11327196.
46. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002, 359(9300):30-36. 10.1016/S0140-6736(02)07276-8, 11809184.
47. Tayeb MT, Clark C, Sharp L, Haites NE, Rooney PH, Murray GI, Payne SN, McLeod HL. CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncol Rep 2002, 9(3):653-655.